-
2seventy Bio NASDAQ:TSVT Its name, 2seventy bio, reflects why 2seventy bio does what 2seventy bio does - TIME. Cancer rips time away and its goal is to work at the maximum speed of translating human thought into action – 270 miles per hour — to give the people 2seventy bio serve more time. 2seventy bio is building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, 2seventy bio’s applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Its research and development is focused on delivering therapies that are designed with the goal to "think" smarter and faster than the disease. Importantly, 2seventy bio remains focused on accomplishing these goals by staying genuine and authentic to its "why" and keeping its people and culture top of mind every day.
Location: | Website: www.2seventybio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
292.1M
Cash
201.9M
Avg Qtr Burn
-37.53M
Short % of Float
11.90%
Insider Ownership
4.08%
Institutional Own.
95.86%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABECMA (IDE-CEL) (bb2121) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
ABECMA (IDE-CE) (bb2121) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
bbT369 Details Cancer, Non-Hodgkin lymphoma, B-cell lymphoma | Phase 1 Update | |
SC-DARIC33 Details Cancer, Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia | Phase 1 Update |